×
Taysha Gene Therapies Receivables 2020-2025 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Taysha Gene Therapies receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
Taysha Gene Therapies Receivables 2020-2025 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Taysha Gene Therapies receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$18.9B
Dr Reddy's Laboratories (RDY)
$12.3B
BridgeBio Pharma (BBIO)
$8.8B
Bausch Health Cos (BHC)
$2.5B
Supernus Pharmaceuticals (SUPN)
$1.9B
Amphastar Pharmaceuticals (AMPH)
$1B
Personalis (PSNL)
$543M
Assembly Biosciences (ASMB)
$149M
Sol-Gel Technologies (SLGL)
$33M
Evoke Pharma (EVOK)
$7M
Teligent (TLGT)
$0M